Konica Minolta Acquires Viztek to Enhance Healthcare IT Solution CapabilitiesWayne, NJ, October 1, 2015 – Konica Minolta, Inc. today announced the completed acquisition of Garner, North Carolina based Viztek, LLC, a leading innovative healthcare company, through Konica Minolta Medical Imaging. With this acquisition, Konica Minolta enhances its capabilities to offer comprehensive, end-to-end healthcare IT solutions from image acquisition to physician diagnosis. It also adds to the established strength
UltraSPECT to Present Xpress Suite of Safer Imaging Solutions at SNMMI 2015SNMMI Attendees Invited to Take Part in New “Hot Trot 5K” Run/Walk to Benefit Professional Development of Nuclear Medicine Technologists Auburndale, Mass., June 1, 2015 (SNMMI Booth #517) – UltraSPECT, a provider of the most cost-effective and vendor-neutral low dose and ultra-low-dose nuclear medicine imaging solutions, will present its Xpress suite of value packages at booth #517 during the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting from June 6-10 in Baltimore, MD. Low dose imaging increases safety for patients and technologists while providing physicians with high-quality images for accurate diagnosis.
20/20 HCP Investment Goes Public: VBL Therapeutics Announces Closing of Initial Public OfferingTEL AVIV, Israel, Oct. 6, 2014 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the closing of its initial public offering of 6,666,667 shares of its common stock at a public offering price of $6.00 share, before underwriting discounts and commissions. As a result, aggregate net proceeds to the Company, after underwriting discounts and commissions and other estimated offering expenses, will be approximately $34.4 million. As previously reported, VBL Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 ordinary shares to cover over-allotments, if any, at the initial public offering price, before underwriting discounts and commissions. The proceeds from the offering are expected to enable the advancement of the company’s development plan in both its Vascular Targeting System® and Lecinoxoid platform technologies through the end of 2016. A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on September 30, 2014. Deutsche Bank Securities is acting as book-running manager for the offering. JMP Securities and Oppenheimer & Co. are acting as co-managers. The offering is being made only by means of a prospectus, copies of which may be obtained from Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, New York 10005-2836, or by calling (800) 503-4611 or emailing a request to email@example.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction. About VBL: Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL Therapeutics’ clinical pipeline is based on two distinct, proprietary platform technologies—an oncology program and an anti-inflammatory program—that leverage the body’s natural physiologic and genetic regulatory elements. The Company’s lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics expects to begin the single needed Phase 3 pivotal trial for VB-111 in rGBM in the first half of 2015 under a SPA whose design and planned analysis the FDA concurred with. VBL Therapeutics’ lead product candidate from its anti-inflammatory program, VB-201, is an oral small molecule currently being evaluated in Phase 2 clinical trials for psoriasis and for ulcerative colitis, with top-line results expected in the first quarter of 2015.